Cinclus Pharma Holding AB (publ)
- Address
- Kungsbron 1 Plan 3 Trappa G
Sponsor Overview
Specializations
Gastroesophageal reflux disease and erosive esophagitis
Clinical activity is centered on GERD and erosive esophagitis, with emphasis on healing, maintenance of healing, and symptom-related disease control in patients with reflux-related mucosal injury.
- Erosive gastroesophageal reflux disease
- Erosive esophagitis due to GERD
- Healing of reflux-associated esophageal lesions
- Maintenance of mucosal healing
The sponsor’s research in this area reflects a strong focus on upper gastrointestinal disorders managed through acid suppression and mucosal protection.
Helicobacter pylori infection
Another area of interest is Helicobacter pylori infection, covering an infectious cause of upper gastrointestinal disease that is closely linked to peptic and gastric pathology.
- Helicobacter pylori
- Upper gastrointestinal infection
- Gastric disease associated with bacterial colonization
This adds an infectious disease dimension to the sponsor’s broader gastrointestinal portfolio.
Acid-related gastrointestinal therapeutics
The funded studies are closely aligned with therapies targeting gastric acid suppression, reflecting interest in treatment options for reflux-mediated injury and related acid-dependent conditions.
- Acid suppression
- Upper gastrointestinal mucosal healing
- Reflux-related disease management
These programs place the sponsor within the therapeutic landscape of gastroenterology and acid-related disorders.
Clinical pharmacology and safety assessment
The portfolio also includes early clinical evaluation of gastrointestinal candidates, with attention to pharmacokinetics and cardiac electrophysiology in healthy participants.
- Pharmacokinetics
- ECG effects
- Healthy participant studies
- Drug interaction assessment
These topics support the clinical development of therapies intended for gastrointestinal disease treatment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Linaprazan Glurate versus Lansoprazole for Maintenance of Healing in Patients with Healed Erosive Esophagitis Due to Gastroesophageal Reflux Disease |  Bulgaria Czechia Germany Hungary Poland Romania | Not Recruiting |
| Evaluation of Linaprazan Glurate Versus Lansoprazole in Healing Erosive Esophagitis Due to Gastroesophageal Reflux Disease: A Phase 3 Randomized Controlled Trial | Bulgaria Czechia Germany Hungary Poland Romania | Not Recruiting |
| Pharmacokinetics and ECG Effects of Linaprazan Glurate in Erosive Gastroesophageal Reflux Disease: A Phase I Study in Healthy Subjects |  Sweden | Not Yet Recruiting |
| Phase 1 Study on Linaprazan Glurate's Impact on Pharmacokinetics of Repeated Antibiotic Doses in Helicobacter pylori Infection and GERD | Sweden | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 67 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases4 trials280 other sponsors
Partnered Research Centres
67 centres- Address
- Semmelweis Utca 1, 5700 Gyula
- Address
- Ul. Kosynierow Gdynskich 61, 93-357 Lodz
- Address
- Podmaniczky Utca 109, 1062 Budapest
- Address
- Ul. Krolowej Jadwigi 16, 85-231 Bydgoszcz
- Address
- Ul. Ul. Ludwika Solskiego 4a/1, 52-416 Wroclaw
- Address
- Kaszasdulo Utca 5, 1033 Budapest
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Cinclus Pharma Holding AB (publ).
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.